World Congress on Thyroid Cancer 3.5
June 20 – 22, 2019
World Congress on Thyroid Cancer 4.0
July 29 – August 1, 2021
WCTC3.5 Steering Committee:
Rocco Bellatone, Co-Chair
Celestino Lombardi, Co-Chair
Gregory W. Randolph, MD
Bryan McIver, MD
Jeremy Freeman, MD
Ian J. Witterick, MD
Ashok R. Shaha, MD
Jatin P. Shah, MD
Bryan Haugen's presentations
- Keynote 3 - Surveillance and Management of Persistent or Recurrent Thyroid Cancer
- Panel Session 2 – Management of Low-Risk Thyroid Cancer
- Panel Session - HOT TOPIC 2 - Radiology vs. Endocrine vs. Surgery Guidelines?
- Panel Session - CONVERSATION WITH THE MASTERS
- IC1 – Thyroid Cancer Guidelines Around the World
Since finishing training at the University of Colorado Health Sciences Center in 1993, Dr. Haugen has been interested in the molecular mechanisms governing thyrotrope function and thyroid neoplasms.
His current clinical interests include thyroid neoplasms, advanced thyroid cancer, thyroid dysfunction and other endocrine tumors (parathyroid, adrenal, carcinoid). Dr Haugen’s research interests include molecular studies of thyroid neoplasm diagnosis and pathophysiology as well as the study of molecular therapeutic targets.
Specific areas of research include nuclear hormone receptors (RXR, TR, PPAR) and kinase signaling pathways as therapeutic targets in thyroid cancer, as well as proteomic approaches to molecular markers in thyroid neoplasms. His research group is also actively studying novel regulation of the hypothalamic-pituitary-thyroid axis.